Search results for "Neovascularization"

showing 10 items of 351 documents

The impact of the receptor binding profiles of the vascular endothelial growth factors on their angiogenic features

2013

Abstract Background Vascular endothelial growth factors (VEGFs) are potential therapeutic agents for treatment of ischemic diseases. Their angiogenic effects are mainly mediated through VEGF receptor 2 (VEGFR2). Methods Receptor binding, signaling, and biological efficacy of several VEGFR2 ligands were compared to determine their characteristics regarding angiogenic activity and vascular permeability. Results Tested VEGFR2 ligands induced receptor tyrosine phosphorylation with different efficacy depending on their binding affinities. However, the tyrosine phosphorylation pattern and the activation of the major downstream signaling pathways were comparable. The maximal angiogenic effect stim…

Vascular Endothelial Growth Factor ASwineAngiogenesisBlotting WesternBiophysicsNeovascularization PhysiologicVascular permeabilityBiologyBiochemistryCapillary Permeabilitychemistry.chemical_compoundCell MovementHuman Umbilical Vein Endothelial CellsNeuropilinAnimalsHumansImmunoprecipitationPhosphorylationReceptorMolecular BiologyAortaCells CulturedCell Proliferationta1182Tyrosine phosphorylationrespiratory systemLigand (biochemistry)Vascular Endothelial Growth Factor Receptor-2Cell biologyVascular endothelial growth factorEndothelial stem cellchemistryBiochemistrycardiovascular systemEndothelium VascularPlasmidsSignal Transductioncirculatory and respiratory physiologyBiochimica et Biophysica Acta (BBA) - General Subjects
researchProduct

Comparative study assessing effects of sonic hedgehog and VEGF in a human co-culture model for bone vascularisation strategies.

2011

The morphogen sonic hedgehog (Shh) seems to mediate adult repair processes in bone regeneration and vascularisation. In this study we investigated the effects of Shh on co-cultures consisting of human primary osteoblasts and outgrowth endothelial cells in terms of angiogenic activation and vessel maturation in comparison to the treatment with the commonly used proangiogenic factor, VEGF. Both, stimulation with VEGF or Shh, leads to an increase in the formation of microvessel-like structures compared to untreated controls. In contrast to VEGF, proangiogenic effects by Shh could already be observed after 24 h of treatment. Nevertheless, after 14 days the angiogenic activity of OEC was compara…

Vascular Endothelial Growth Factor Alcsh:Diseases of the musculoskeletal systemBone Regenerationmedicine.medical_treatmentFluorescent Antibody TechniqueAngiogenesis InhibitorsPolymerase Chain ReactionneovascularisationBasement MembraneDesminchemistry.chemical_compoundTransforming Growth Factor betaReceptors Platelet-Derived Growth FactorSonic hedgehogbiologyCell biologyUp-Regulationembryonic structuresElectrophoresis Polyacrylamide GelMorphogenmedicine.medical_specialtyanimal structuressignalling moleculesCyclopamineBlotting Westernlcsh:SurgeryNeovascularization PhysiologicEnzyme-Linked Immunosorbent AssayBone and BonesDownregulation and upregulationInternal medicinemedicineAngiopoietin-1HumansHedgehog ProteinsBone regenerationOsteoblastsGrowth factorEndothelial Cellslcsh:RD1-811bone repairco-cultureActinsCoculture TechniquesEndocrinologychemistryMyocardinbiology.proteinDesminlcsh:RC925-935AngiopoietinsEuropean cellsmaterials
researchProduct

Capillary enlargement, not sprouting angiogenesis, determines beneficial therapeutic effects and side effects of angiogenic gene therapy.

2010

Aims Currently, it is still unclear which mechanisms drive metabolic benefits after angiogenic gene therapy. The side-effect profile of efficient angiogenic gene therapy is also currently incompletely understood. In this study, the effects of increasing doses of adenoviral (Ad) vascular endothelial growth factor-A (VEGF-A) were evaluated on vascular growth, metabolic benefits, and systemic side effects. Methods and results Adenoviral vascular endothelial growth factor-A or AdLacZ control was injected intramuscularly (109–1011 vp/mL) or intra-arterially (5 × 1011 vp/mL) into rabbit ( n = 102) hindlimb muscles and examined 6 or 14 days later. Blood flow, tissue oedema, metabolic benefits, and…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyAngiogenesisGenetic VectorsNeovascularization PhysiologicEnzyme-Linked Immunosorbent Assayta3111Injections IntramuscularAdenoviridaeNeovascularizationchemistry.chemical_compoundInternal medicinemedicineAnimalsMuscle SkeletalUltrasonography InterventionalSprouting angiogenesisDose-Response Relationship Drugbusiness.industryGene Transfer TechniquesMetabolic acidosisGenetic Therapymedicine.diseaseCapillariesHindlimbVascular endothelial growth factorVascular endothelial growth factor AEndocrinologychemistryLac OperonCirculatory systemRabbitsmedicine.symptomCardiology and Cardiovascular MedicinebusinessPerfusionEuropean heart journal
researchProduct

Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis

2009

Survival of newly implanted retrograde-shed endometrial tissue during menstruation in an ectopic location requires an adequate blood supply. This suggests that angiogenesis is a prerequisite for the development of endometriosis and that its inhibition may be a target for preventing development. Previous studies have shown that vascular endothelial growth factor (VEGF), a heparin-binding glycoprotein, has an essential role in angiogenesis. The main regulatory factor for angiogenesis appears to be binding of VEGF to its type-2 receptor (VEGFR-2). Cabergoline (Cb2) and other dopamine agonists promote endocytosis of the VEGF receptor-2 (VEGFR-2) in endothelial cells, thereby preventing VEGF-VEG…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyCabergolineProliferation indexAngiogenesisEndometriosisEndometriosisBiologyEndometriumDopamine agonistMicechemistry.chemical_compoundPeritoneumCabergolineInternal medicinemedicineAnimalsHumansErgolinesPhosphorylationReceptorCell ProliferationNeovascularization Pathologicbusiness.industryRehabilitationObstetrics and GynecologyKinase insert domain receptorGeneral Medicinemedicine.diseaseVascular Endothelial Growth Factor Receptor-2Vascular endothelial growth factorDisease Models AnimalVascular endothelial growth factor AEndocrinologymedicine.anatomical_structureGene Expression RegulationReproductive MedicinechemistryDopamine AgonistsFemalelipids (amino acids peptides and proteins)businessmedicine.drugHuman Reproduction
researchProduct

Tyrosine Phosphorylation Modulates the Vascular Responses of Mesenteric Arteries from Human Colorectal Tumors

2013

The aim of this study was to analyze whether tyrosine phosphorylation in tumoral arteries may modulate their vascular response. To do this, mesenteric arteries supplying blood flow to colorectal tumors or to normal intestine were obtained during surgery and prepared for isometric tension recording in an organ bath. Increasing tyrosine phosphorylation with the phosphatase inhibitor, sodium orthovanadate produced arterial contraction which was lower in tumoral than in control arteries, whereas it reduced the contraction to noradrenaline in tumoral but not in control arteries and reduced the relaxation to bradykinin in control but not in tumoral arteries. Protein expression of VEGF-A and of th…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyContraction (grammar)Article SubjectMedicinaBradykininlcsh:MedicineBiologyGeneral Biochemistry Genetics and Molecular BiologyTyrosine phosphorylationchemistry.chemical_compoundOrgan Culture TechniquesInternal medicinemedicineHumansPhosphorylationTyrosineSodium orthovanadateMesenteric arteriesVascular Endothelial Growth Factor Receptor-1Neovascularization PathologicGeneral Immunology and Microbiologylcsh:RTyrosine phosphorylationGeneral MedicineMesenteric ArteriesGene Expression Regulation NeoplasticVascular endothelial growth factor AEndocrinologymedicine.anatomical_structurechemistryTyrosinePhosphorylationVanadatesColorectal NeoplasmsResearch ArticleBioMed Research International
researchProduct

Sonic hedgehog promotes angiogenesis and osteogenesis in a coculture system consisting of primary osteoblasts and outgrowth endothelial cells.

2009

A number of previous studies documented the angiogenic potential of outgrowth endothelial cells in vitro and in vivo and provided evidence that therapeutic success could depend on coculture or coimplantation strategies. Thus, deeper insight into the molecular mechanisms underlying this pro-angiogenic effect of cocultures might provide new translational options for tissue engineering and regenerative medicine. One promising signaling pathway in bone repair involved in neoangiogenesis and bone formation is the sonic hedgehog (Shh) pathway. In this article, we focus on the effect of Shh on the formation of microvessel-like structures and osteoblastic differentiation in cocultures of primary os…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyCyclopamineAngiogenesisCellular differentiationBiomedical EngineeringNeovascularization PhysiologicBioengineeringBiochemistryBiomaterialsAngiopoietin-2chemistry.chemical_compoundOsteogenesisInternal medicinemedicineAngiopoietin-1HumansHedgehog ProteinsRNA MessengerSonic hedgehogBone regenerationDNA PrimersOsteoblastsbiologyBase SequenceTissue EngineeringVeratrum AlkaloidsEndothelial CellsCell DifferentiationOriginal ArticlesHedgehog signaling pathwayCoculture TechniquesRecombinant ProteinsCell biologyCapillariesUp-RegulationVascular endothelial growth factorVascular endothelial growth factor AEndocrinologychemistrybiology.proteinSignal TransductionTissue engineering. Part A
researchProduct

Risk of Death Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-analysis.

2020

Importance Although intravitreal anti–vascular endothelial growth factor (VEGF) treatment represents the first-line therapy for many retinal diseases, the issue of their systemic safety is debatable. Objectives To assess whether intravitreal anti-VEGF therapy might be associated with increased risk of mortality and which variables are associated with the increase. Data Sources PubMed, MEDLINE, and Embase databases, the Cochrane Library, and ClinicalTrials.gov were systematically searched from inception to May 6, 2019. Study Selection Randomized clinical trials comparing intravitreal anti-VEGF treatment with control groups and with follow-up of at least 6 months were selected. Data Extractio…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyDatabases FactualMEDLINEAngiogenesis InhibitorsCochrane LibraryMacular Edemalaw.inventionRandomized controlled triallawFrequentist inferenceInternal medicineCause of DeathRetinal Vein OcclusionMedicineHumansanti-VEGF therapyrisk of mortality anti-vascular endothelial growth factor mortalityCause of deathOriginal InvestigationRandomized Controlled Trials as TopicDiabetic Retinopathybusiness.industryMortality rateOdds ratioChoroidal NeovascularizationOphthalmologyMeta-analysisIntravitreal InjectionsWet Macular DegenerationbusinessJAMA ophthalmology
researchProduct

From the oxygen to the organ protection: Erythropoietin as protagonist in internal medicine

2006

Erythropoietin (EPO), already known as the stimulating hormone for erythropoiesis, has shown different and interesting pleiotropic actions. It does not only affect erythroid cells, but also myeloid cells, lymphocytes and megakaryocytes. This hormone can also enhance phagocytic function of the polymorphonuclear cells and reduce the activation of macrophages, thus modulating the inflammatory process.Moreover, hematopoietic and endothelial cells probably have the same cellular origin, and the discovery of erythropoietin receptors (EPO-R) also on mesangial and myocardial cells, smooth muscle fibrocells and neurons has prompted the study of the non-erythropoietic functions of this hormone.The in…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyIschemiaNeovascularizationIschemiahemic and lymphatic diseasesInternal medicinemedicineErythropoietin (EPO); pleiotropic actions; erythropoietin receptors (EPO-R); VEGFHumansOxygen tensionReceptorHypoxiaErythropoietinPharmacologyClinical Trials as Topicbusiness.industryPleiotropic actionerythropoietin receptors (EPO-R)pleiotropic actionsAngiogenesis Modulating AgentsApoptosiAnemiaShockHematologymedicine.diseaseVEGFHaematopoiesisAngiogenesiEndocrinologyApoptosisErythropoietinErythropoietin (EPO)Erythropoiesismedicine.symptombusinessCardiology and Cardiovascular MedicineHormonemedicine.drugReceptor
researchProduct

Priming with a combination of proangiogenic growth factors improves wound healing in normoglycemic mice

2011

Growth factors and/or angiogenic factors are supposed to improve wound healing. The aim of our study was to evaluate the effects of subcutaneous pretreatment with combinatory proangiogenic factors on wound closure, mechan - ical properties, vessel density and morphology. Twenty-eight Balb/c mice were divided equally into two groups. A mixture of VEGF (35.0 µg), bFGF (2.5 µg) and P dGF (3.5 µg) was administered subcutaneously 3, 5 and 7 days to 14 mice before full thickness skin punch biopsy wounding, whereas 14 control animals received three injections of 0.2 ml saline solution. Wound sizes were assessed daily and the repaired tissues were harvested 7 days after complete wound closure. Comp…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyPlatelet-derived growth factormedicine.medical_treatmentInjections SubcutaneousUrologyPriming (immunology)Neovascularization PhysiologicArticlechemistry.chemical_compoundMiceSkin Physiological PhenomenaTensile StrengthGeneticsmedicineAnimalsRegenerationSalineSkinPlatelet-Derived Growth FactorMice Inbred BALB CWound HealingOncogeneintegumentary systembusiness.industryGeneral MedicineMolecular medicineSurgeryVascular endothelial growth factor ADrug CombinationsCollagen Type IIIchemistryApoptosisThermographyBlood VesselsAngiogenesis Inducing AgentsFemaleFibroblast Growth Factor 2Wound healingbusiness
researchProduct

Protein kinase C   promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor

2008

Aims Protein kinase C (PKC) plays an important role in the regulation of angiogenesis. However, downstream targets of PKC in endothelial cells are poorly defined. Methods and results mRNA expression of vascular endothelial growth factor (VEGF) was analysed by quantitative real-time RT-PCR in human umbilical vein endothelial cells (HUVEC) and HUVEC-derived EA.hy 926 cells. siRNA was used to knockdown PKC isoforms and VEGF. Matrigel tube formation assay was used to analyse the angiogenic activity of endothelial cells. Phorbol-12-myristate-13-acetate (PMA) enhanced the ability of HUVEC to organize into tubular networks when plated on Matrigel, a phenomenon that could be prevented by PKC inhibi…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyProtein Kinase C-alphaTime FactorsPhysiologyAngiogenesismedicine.medical_treatmentBlotting WesternCarbazolesNeovascularization PhysiologicBiologyPolymerase Chain ReactionCell Linechemistry.chemical_compoundPhysiology (medical)Internal medicinemedicineHumansRNA MessengerRNA Small InterferingCell ShapeProtein Kinase InhibitorsCells CulturedProtein kinase CTube formationMatrigelStem CellsGrowth factorEndothelial CellsUp-RegulationCell biologyEnzyme ActivationEndothelial stem cellVascular endothelial growth factorAutocrine CommunicationVascular endothelial growth factor AReceptors Vascular Endothelial Growth FactorEndocrinologychemistryTetradecanoylphorbol AcetateAngiogenesis Inducing AgentsFibroblast Growth Factor 2RNA InterferenceCardiology and Cardiovascular MedicineCardiovascular Research
researchProduct